To explore the modulatory effects of IL-2-activated NK cells on hematopoietic stem cell (HSC) engraftment further, we used fresh newborn liver cells (NLC) and IL-2-activated newborn liver cells (ANLC) as combined sources, respectively, of transplanted HSC and IL-2-activated NK cells free of contaminating CD3 + T cells. As previously found with adult IL-2-activated spleen cells, NLC cultured with IL-2 for 7 days exhibited lymphokine-activated killer (LAK) activity, veto activity, and natural suppressor activity, and enhanced both short-term and long-term stem cell engraftment by intact co-injected syngeneic and allogeneic NLC in totally MHC-mismatched lethally irradiated recipients.
vious findings suggest that it may be possible to overcome the high risk of lethal GVHD and graft rejection in human recipients of MHC-mismatched stem cells by combined transplantation of T cell-depleted stem cells together with IL-2-activated NK cells.
Recently, there has been increasing interest in the use of placental blood as a convenient and readily available source of transplantable hematopoietic stem cells. Placental blood transplants have been associated with successful stem cell engraftment and a reduced severity of GVHD, even in HLA-mismatched unrelated recipients. 4, 5 If IL-2-activated placental blood NK cells function in vivo like adult murine IL-2-activated NK cells, it might be possible to achieve safe and effective stem cell engraftment in completely MHCmismatched recipients by use of T cell-depleted IL-2-activated placental blood cells. However, concern about the functional equivalence of newborn and adult NK cells arises from the fact that NK cells from newborn humans and mice have relatively low NK activity compared to NK cells from adults. 6, 7 With that in mind, we have carried out experiments with intact and IL-2-activated murine newborn liver cells as homologs of human intact and IL-2-activated T cell-depleted placental blood cells. The purpose of these studies was to determine whether IL-2-activated NK cells from newborns exhibit in vitro and in vivo functional activities of possible relevance to clinical hematopoietic stem cell transplantation similar to those of IL-2-activated NK cells from adults. ) mice aged 4-10 weeks were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Newborn B6, BALB/c and C3B6F mice aged 0-2 days were obtained from our own breeding colony.
Materials and methods

Mice
Preparation of bone marrow, liver and spleen cells
Bone marrow suspensions were prepared by flushing excised long bones with cold RPMI 1640 using a syringe and a 27 gauge needle. Single cell suspensions of fresh newborn liver and adult spleen cells were obtained by passage through wire mesh and removal of large clumps by gravity sedimentation. Newborn liver cells from individual litters were pooled, aliquoted and stored frozen in 10% DMSO-90% fetal calf serum at Ϫ170°C.
IL-2-stimulation of newborn liver cells
Single cell suspensions of thawed and washed frozen-stored newborn liver cells were cultured at 5 million cells/ml in complete medium (RPMI 1640 supplemented with 10% fetal bovine serum, 5 ϫ 10 Ϫ5 m 2-mercaptoethanol, 20 mm HEPES, 100 mm sodium pyruvate, 10 mm nonessential amino acids, and 50 g/ml gentamicin) containing 1000 international units/ml human rIL-2 (Chiron, Emeryville, CA, USA). Prior to testing, IL-2-stimulated newborn liver cells were washed three times in medium.
Cell preparation, analysis and sorting of IL-2-activated cells
Frozen-stored newborn liver cells and adult spleen cells from C57BL/6 mice were thawed, washed and cultured in complete medium containing 1000 units/ml recombinant human IL-2. At various times of culture, the cells were harvested and were double-stained with PE-anti-NK1.1 mab and either FITC anti-mouse CD3⑀ mab or FITC-anti-2B4 mouse (Pharmingen, San Diego, CA, USA). Control cells were stained with appropriate isotype control mabs. The stained cells were analyzed on an EPICS XL-MCL flow cytometer gated on mononuclear cells by simultaneous 90°and forward angle light scatter. In some experiments, B6 newborn liver cells cultured for 14 days with IL-2 and double-stained for NK1.1 and CD3 were sorted into NK1.1 + and NK1.1 Ϫ populations on a FACS Vantage flow cytometer (Becton Dickinson, San Jose, CA, USA) using CellQuest software with ILT laser set at 488 nm excitation wavelength and 40 mW power.
Mixed lymphocyte cultures
Mixed lymphocyte cultures were set up in tissue culture wells in 3 ml complete medium with 5 ϫ 10 6 adult BALB/c responder spleen cells and equal numbers of mitomycin-Ctreated fresh adult B6 and A/J stimulator spleen cells (ie 5 ϫ 10 6 of each). Variable numbers of B6 newborn liver cells which had been cultured for 7 days in IL-2 were added at day 0 of MLC. After 5 days incubation at 37°C in a humidified chamber containing 5% CO 2 , the MLC cells were harvested and tested for allo-CTL activity against each of the stimulator-type ConA blasts, as described below.
Cell mediated cytotoxicity assays
Target cells in cell-mediated cytotoxicity assays for LAK activity were NK-insensitive P815 murine tumor line cells maintained in suspension culture in RPMI 1640 with 10% fetal bovine serum. Target cells in assays of mixed lymphocyte culture (MLC)-induced allocytotoxic T cell (allo-CTL) activity were ConA blasts (spleen cells cultured for 2-3 days with 5 g/ml ConA). All target cells were CrO 4 (New England Nuclear, Boston, MA, USA) for 60 min at 37°C followed by three washes.
Variable numbers of effector cells were added to 10 4 isotope-labeled target cells in V-bottom microtiter wells in a final volume of 0.2 ml complete medium. The plates were centrifuged at 40 g for 5 min and then incubated at 37°C in a humidified chamber containing 5% CO 2 . After 4 h the plates were centrifuged at 400 g for 5 min, and 0.1 ml of supernatant fluid was collected and counted in an autogamma counter. Spontaneous 51 Cr release was determined by incubation of target cells with medium alone. The % specific lysis was calculated as 100 × (EϪS/TϪS) where E is the experimental 51 Cr release, S is the spontaneous release, and T is the total incorporated counts. All experimental and control values were means of three replicate determinations. This data was used to calculate lytic units (LU) as previously described, 6 where one LU is defined as the number of effector cells required to lyse 20% of 10 4 target cells.
Irradiation
Mice were irradiated at a rate of 110 cGy/min from a 137 Cs source (Gamma Cell 40; Atomic Energy of Canada, Ottawa, Canada).
Assays for short-term and long-term stem cell engraftment
Mice were exposed to lethal irradiation (BALB/c, 750 cGy; C3B6F1 850 cGy). Four hours later groups of at least three mice were infused by tail vein injection with 5 ϫ 10 5 fresh frozen-stored syngeneic or allogeneic newborn liver cells with or without added syngeneic or allogeneic IL-2-stimulated newborn liver cells cells. To assess short-term stem cell engraftment, recipient spleens were removed after 7 days, and splenic foci (CFU-S) were enumerated as described by Till and McCulloch. 8 To assess long-term engraftment, recipient BALB/c mice were observed daily for general condition and for survival. Mice from different groups surviving more than 25 days were killed at 45 days or 90 days post-transplant, and their spleen cells were then tested for chimerism by FACS. 
Assay for chimerism
Statistical analysis
Mean differences for CFU-S were analyzed by ANOVA with post-hoc comparisons using Statview 4.0 statistical software (Abacus Concepts, Berkeley, CA, USA). Differences in survival of mice in long-term stem cell engraftment experiments were analyzed by the nonparametric rank sum method of Wilcoxon.
9
Results
FACS analysis of T cell and NK cell differentiation markers
Pools of frozen-stored C57Bl/6 (B6) newborn liver cells were cultured in complete medium containing 1000 units/ml recombinant human IL-2. At various times of culture the cells were harvested and stained with fluorochrome-conjugated monoclonal antibodies to the NK cell markers NK1.1 and 2B4, and to the T cell marker CD3⑀. Positively stained cells were then enumerated by FACS analysis. As shown in Figure 1 , fresh and 3 day IL-2-stimulated newborn liver cells contained few if any CD3
+ , or NK1.1 + cells. After 11 days of culture with IL-2, less than 1% of the cells were CD3
+ , but roughly 16% of the cells now expressed the NK cell marker NK1.1 and 81% expressed 2B4, another NK cell marker. After 17 days in culture, cells expressing CD3 remained at less than 1%; however, all of the cells now expressed 2B4, and roughly 50% expressed NK1.1. In addition, roughly 50% expressed Thy1.2 (66% of which were NK1.1 Ϫ ), and none expressed Ly49C (data not shown).
LAK activity of frozen-stored IL-2-stimulated newborn liver cells
Frozen-stored B6 newborn liver cells cultured for various periods of time with 1000 U/ml recombinant human IL-2 were tested for LAK-type cytolytic activity against NKresistant tumor cell line P815. Although LAK activity was minimal after 2 days culture with IL-2, it was readily apparent after 3 days culture, and further increased after 7 days culture ( Figure 2 ). Thus newborn liver cells readily generate LAK activity. The 1-2 day delay in IL-2-induced generation of LAK-type cytotoxicity as compared to the rapid 
Veto activity and natural suppressor activity of IL-2-stimulated newborn liver cells
Varying numbers of liver cells from newborn B6 mice cultured 7 days with 1000 U/ml IL-2 were added at the time of culture initiation to mixed lymphocyte cultures containing H-2 d BALB/c responder spleen cells and 2000 cGyirradiated H-2 b B6 and H-2 a A/J stimulator cells. Control mixed lymphocyte cultures contained no added newborn liver cells (NLC). Allospecific cytotoxicity against blasts from stimulator-type mice was measured on day 5 of culture. When added in relatively small numbers, IL-2-stimulated B6 NLC exhibited veto activity:
10 they specifically inhibited generation of anti-B6 CTL but not anti-A/J CTL ( Figure 3) . When added at relatively higher numbers, these same cells exhibited natural suppressor activity; ie they nonspecifically inhibited generation of both anti-A/J and anti-B6 CTL. Using NK clones in similar assays, we have previously obtained evidence that a single IL-2-activated NK cell can mediate both activities.
11 However, our current data does not exclude the possibility that distinct subsets of IL-2-activated newborn liver cells could mediate these two distinct functional activities. 
IL-2-stimulated newborn liver cells enhance short-term engraftment of newborn hematopoietic stem cells in semisyngeneic and totally allogeneic recipients
Fetal and newborn liver cells have been shown to be more susceptible to hematopoietic stem cell graft rejection than adult bone marrow cells. 12, 13 In light of this and previous findings that IL-2-activated adult NK-type LAK cells enhance HSC alloengraftment of adult bone marrow cells, [1] [2] [3] we sought to determine whether IL-2-activated NLC could either specifically or nonspecifically enhance HSC engraftment by coinjected NLC in semisyngeneic or allogeneic recipients. Lethally irradiated H-2 k/b C3B6F1 mice (900 cGy) or H-2 d BALB/c mice (750 cGy) were injected i.v. with 5 ϫ 10 5 NLC from 1-day-old H-2 b B6 or BALB/c mice together with 5 ϫ 10 6 B6 NLC that had been cultured in 1000 U/ml IL-2 for 8-12 days, a duration of culture found to deplete hematopoietic stem cells. Thus, injection of 5 million 8-12-day IL-2-stimulated B6 or BALB/c NLC alone failed to generate CFUs in lethally irradiated syngeneic recipients.
As shown in Figures 4a and b , compared to the 20-50 CFU-S/spleen generated by 5 ϫ 10 5 syngeneic NLC in C3B6F1 and BALB/c recipients, few if any CFU-S were generated following injection of these same mice with similar numbers of semisyngeneic or totally allogeneic fresh B6 or BALB/c NLC. Coinjection of 8-day IL-2-activated B6 NLC partially overcame resistance of C3B6F1 mice to stem cell engraftment by coinjected fresh B6 NLC (P Ͻ 0.05), but failed to significantly affect the resistance of these mice to stem cell engraftment by MHC-disparate fresh BALB/c NLC. By contrast, both donor-type B6 and host-type BALB/c-derived 12-day IL-2-activated NLC overcame allogeneic resistance of BALB/c recipients to HSC engraftment by coinjected fresh B6 NLC. Therefore, IL-2-activated NLC appear to exert both antigen-specific and non-specific enhancing effects on short-term engraftment of coinjected HSC in allogeneic and semisyngeneic recipients.
NK1.1 Ϫ 2B4 + NK cell subset mediates enhancement of short-term HSC engraftment by IL-2-activated newborn liver cells
Cells belonging to the NK lineage appear to be responsible for the ability of 12-17-day IL-2-activated NLC to enhance short-term HSC alloengraftment since by day 16 
CD3, the only CD3
+ cells detected were those which also expressed NK1.1; none of the NK1.1-negative cells expressed CD3 (Figure 5b) . To compare the enhancer cell activity of these two IL-2-activated NK cell subsets, we sorted 16-day IL-2-activated B6 newborn liver cells into NK1.1 + and NK1.1 Ϫ populations, and compared their effects on short-term HSC engraftment of coinjected B6 NLC in lethally irradiated totally allogeneic BALB/c mice. As shown in Figure 6 , coinjection of relatively low numbers (15 ϫ 10 5 ) of NK1.1 Ϫ 16-day IL-2-activated NLC completely abrogated resistance of BALB/c recipients to stem cell engraftment with fresh B6 NLC whereas coinjection of similar numbers of NK1.1 + IL-2-activated NLC had no effect.
IL-2-stimulated newborn liver cells enhance long-term engraftment of newborn liver-derived hematopoietic stem cells in allogeneic recipients
To test the ability of IL-2-activated NLC to enhance longterm HSC alloengraftment, lethally irradiated (750 cGy) BALB/c mice were injected with 2 million allogeneic B6 NLC either alone or together with 5 million B6 NLC cultured 7 days with 1000 U/ml IL-2. Controls included uninjected mice, and mice injected with 2 million syngeneic BALB/c bone marrow, 10 million B6 NLC, or 2 million IL-2-activated B6 NLC alone. Survival was monitored daily, and donor cell chimerism was measured by staining recipient spleen cells for donor-type H-2D b or recipienttype H-2D d on days 50 or 90 post-transplant. As expected . By contrast, a significantly lower fractional survival was observed in the 13 BALB/c recipients of the five-fold lower dose of 2 million B6 NLC (group C) (P Ͻ 0.05). Three mice from this group were sacrificed at day +50 post-transplant to check for chimerism, and FACS analysis revealed that the spleen cells from two of these mice uniformly stained for recipient-type H- stimulated ϫ 7 days with IL-2 survived at least 90 days, and by FACS analysis spleen cells from all six of these so tested were primarily donor-type H-2D b . The enhanced survival seen in this group was not due to rescue by HSCs in the IL-2-activated NLC since none of the six recipients receiving 5 million B6 ANLC alone survived longer than 18 days. Of interest, despite engraftment with completely allogeneic B6 cells, none of the mice in the groups transplanted with either 10 million intact B6 NLC alone, or the combination of intact and IL-2-activated B6 NLC showed clinical signs of graft-versus-host disease (hunched posture, ruffled fur, weight loss).
Discussion
The results indicate that IL-2-activated mouse newborn liver NK cells, like IL-2-activated adult mouse NK cells, have LAK activity, veto activity, and natural suppressor activity, and facilitate long-term as well as short-term engraftment of coinjected newborn liver HSC in totally MHC-mismatched recipients without themselves causing acute GVHD. The failure of IL-2-activated newborn liver cells to cause GVHD is almost certainly due to the fact that although they contain activated NK cells they contain few if any CD3
+ T cells, a cell type required for induction of GVHD. Thus, IL-2-activated NK cells fail to cause GVHD in the absence of donor-type CD3 + T cells. Abundant evidence now indicates that NK cells comprise multiple subsets characterized by differential expression of polymorphic cell surface receptors for target cell MHC class I molecules and other moieties.
14 In addition to differences in their target cell specificities, these NK cell subsets also differ in other functions related to hematopoiesis. In H-2 d mice, the NK cell subset which expresses Ly49C promotes hematopoietic growth of stem cells in syngeneic recipients by releasing hematopoietic growth factors, whereas the Ly49C-negative NK cell subset inhibits such growth. 15 The findings presented here demonstrate that the 12-17-day IL-2-activated newborn liver NK enhancer cells of short-term hematopoietic stem cell engraftment belong to the relatively immature CD3 Ϫ NK1.1 Ϫ 2B4 + NK cell subset and lack Ly49 molecules. The more mature CD3 Ϫ NK1.1 + 2B4 + NK cells present in these same cultures also lack Ly49 molecules, but exhibit no stem cell enhancing effect. These two functionally distinct NK1. Given that virtually all 7-day IL-2-cultured NLC express the NK marker 2B4, it seems clear that IL-2-activated NK cells are responsible for enhancing long-term stem cell engraftment just as they are responsible for enhancing short-term stem cell engraftment. However, the relative roles of the NK1.1 Ϫ and NK1.1 + 2B4 + NK cell subsets remains to be determined. In this regard, it should be noted that Blazar et al 17 previously reported that in contrast to depletion of Thy1 + cells, depletion of donor marrow NK1.1 + cells did not impair long-term engraftment in allogeneic recipients. In light of the present findings, these earlier observations provide indirect evidence that NK cell enhancers of long-term stem cell engraftment may belong to the immature NK1.1 Ϫ 2B4 + NK cell subset. In any case, the NK 'enhancer' cells detected here appear to differ from 'facilitator' cells previously detected in normal adult bone marrow 18 since the latter express cell surface CD3, a definitive T cell marker, whereas the former do not.
Davenport et al 13 previously showed that HSCs in murine newborn liver cell suspensions are more susceptible to rejection by allogeneic recipients than are HSCs in adult bone cell suspensions. This appears to be due in part to a lack of mature T cells in NLC suspensions since it can be overcome by coinjection of donor-type adult thymocytes. However, the mechanism(s) by which adult T cells enhance alloengraftment of NLC have not been established. Given the fact that T cells are the cells primarily responsible for production of IL-2, our finding that IL-2-stimulated NLCs which contain few if any T cells can also overcome alloresistance to NLC stem cells raises the possibility that donortype T cells may, in part, act indirectly through cohort NK cells. Thus, following injection into the recipient, donor T cells may be stimulated by recipient alloantigens to produce IL-2 which in turn activates coinjected donor NK cells to facilitate engraftment of cohort HSCs. The extent to which T cells enhance HSC alloengraftment by NK-dependent or NK-independent mechanisms, and the extent to which NK cells enhance HSC alloengraftment by T cell-dependent and T cell-independent mechanisms requires further analysis.
There has been growing interest in the use of placental blood as a source of stem cell transplantation; it is readily available, and its use is associated with a relatively low incidence of severe acute or chronic GVHD. 4 With that in mind, we are seeking to identify IL-2-activated placental blood NK cells with stem cell enhancing properties similar to those detected here with IL-2-activated murine newborn liver NK cells. Identification of such cells might provide a relatively safe and effective approach to enhancing engraftment of hematopoietic stem cells in unrelated MHCmismatched recipients.
